Analysis of the predictive value of HCV RNA results measured with real-time polymerase chain reaction (PCR) assay for response-guided therapy in chronic Hepatitis C virus infection

2012 ◽  
Vol 50 (05) ◽  
Author(s):  
J Gervain
2009 ◽  
Vol 48 (8) ◽  
pp. 1152-1159 ◽  
Author(s):  
Eva Van den Eynde ◽  
Manuel Crespo ◽  
Juan I. Esteban ◽  
Rosend Jardi ◽  
Esteban Ribera ◽  
...  

2012 ◽  
Vol 2 (2) ◽  
pp. 9-13
Author(s):  
Hisham O. Akbar

Background: PEGylated interferon and ribavirin therapy is the current standard of care for patients with chronic Hepatitis C virus. It is unknown whether retreatment may be beneficial in non-responders. Methods: Patients who failed to respond to either PEG-Intron or Pegasys with ribavirin were switched to a different PEGylated interferon with ribavirin. Patients were assessed for virologic response by a decrease in viral load levels using a polymerase chain reaction assay. Only patients who had a negative viral load at week 24 were allowed to continue treatment for 48 weeks. Patients with a negative polymerase chain reaction assay after 6 months off treatment were considered as responders to the retreatment regimen. Results: A total of 16 patients were retreated. The combination of Pegasys and ribavirin was administered to 3 patients, and 13 patients received PEG-Intron with ribavirin. Patients had either genotype 1 or 4. Only 4 patients responded to retreatment with PEG-Intron (25%). The responders were female, had a low viral load and had an early significant viral load reduction. Three patients had genotype 4, and one had genotype 1. Conclusion: Retreatment with different PEGylated interferon in patients who failed previous treatment may have a role in the selected patients infected with chronic Hepatitis C virus.


1999 ◽  
Vol 19 (3) ◽  
pp. 383-388 ◽  
Author(s):  
Fabrizio Fabrizi ◽  
Paul Martin ◽  
Vivek Dixit ◽  
Maria Brezina ◽  
James Russell ◽  
...  

Blood ◽  
1996 ◽  
Vol 88 (7) ◽  
pp. 2768-2774 ◽  
Author(s):  
L Muratori ◽  
D Gibellini ◽  
M Lenzi ◽  
M Cataleta ◽  
P Muratori ◽  
...  

Hepatitis C virus (HCV) is known to infect peripheral blood mononuclear cells (PBMC) of patients with chronic hepatitis C, but the proportion of HCV-infected circulating cells is not detectable by conventional reverse transcriptase-polymerase chain reaction (RT-PCR) and the pathogenic significance of HCV lymphotropism is still unclear. Therefore, we have devised an in situ RT-PCR technique using fluorescein-labeled HCV-specific primers revealed by flow cytometry. PBMC were isolated from 28 patients with chronic HCV-related liver disease; of these, 6 had previously received an orthotopic liver transplantation (OLT) and were on immuno-suppressive treatment. Fourteen patients (50%) were found positive for HCV genome within PBMC by in situ RT-PCR, the proportion of HCV-infected cells ranging from 0.2% to 8.1%. All 6 OLT patients tested positive. The fluorescent signal, corresponding to the HCV-specific 340-bp amplicon, was confined to part of the cytoplasmic compartment of scattered PBMC. Of these 14 patients, 12 had also negativestrand HCV RNA within PBMC detected by “tagged” RT-PCR. We conclude that HCV may infect a significant proportion of PBMC in chronic hepatitis C patients, especially immunosuppressed OLT cases, and that viral replication within PBMC is a common occurrence. Over time, the persistence of HCV-infected immune system cells might interfere with normal immunologic mechanisms and play a role in the pathogenic processes leading to extrahepatic disorders such as mixed cryoglobulinemia and B-cell malignant lymphoma.


Sign in / Sign up

Export Citation Format

Share Document